Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

NCT05899816 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT05899816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05899816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Rocatinlimab on Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
June 7, 2023
Completion date
November 14, 2024
Enrollment
221 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis, moderate-to-severe atopic dermatitis